MannKind (MNKD) vs Taysha Gene Therapies (TSHA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
Taysha Gene Therapies (TSHA) has outperformed MannKind (MNKD) over the past year, losing 12.5% versus a loss of 38.9%. Over five years, MNKD leads with a -32.2% price change compared with -75.2% for TSHA. Taysha Gene Therapies is the larger company by market cap ($1.44 billion vs $1.10 billion), about 1.3 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | MNKD | TSHA |
|---|---|---|
| Share price | $3.42 | $4.43 |
| Market cap | $1.10B | $1.44B |
| 1-day change | -0.87% | 0.00% |
| YTD return | -39.15% | -19.45% |
| 1-year return | -38.94% | -12.45% |
| 5-year return | -32.22% | -75.22% |
| Forward P/E | 26.82 | — |
| EPS (TTM) | $-0.14 | $-0.41 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $6.51 | $7.30 |
| 52-week low | $2.23 | $3.69 |
| Distance from 52-week high | -47.47% | -39.32% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +129.24% | +193.45% |
| Average volume | 4.50M | 3.28M |
| Shares outstanding | 321.54M | 325.83M |
| Employees | 591 | 99 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- TSHA has outperformed MNKD by 26.5 percentage points over the past year.
About MannKind
MNKD stock →MannKind Corporation, a biopharmaceutical company, focuses on the provision of various solutions for transforming chronic disease care. It develops and commercializes treatments that address various unmet medical needs, including diabetes, pulmonary hypertension, and fluid overload in heart failure and chronic kidney disease.
Healthcare · Biotechnology · 591 employees
About Taysha Gene Therapies
TSHA stock →Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of severe monogenic diseases of the central nervous system. The company primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; and TSHA-114 for the treatment of fragile X syndrome.
Healthcare · Biotechnology · 99 employees
MNKD vs TSHA FAQ
Which is bigger, MannKind or Taysha Gene Therapies?
Taysha Gene Therapies (TSHA) is larger, with a market capitalization of $1.44B compared with $1.10B for MannKind (MNKD).
Which stock has performed better over the past year, MNKD or TSHA?
TSHA returned -12.45% over the past 12 months, compared with -38.94% for MNKD (price return, excluding dividends). Past performance does not predict future results.
Are MannKind and Taysha Gene Therapies in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.